Literature DB >> 12525273

The role of anticonvulsants in preventive migraine therapy.

Jill Corbo1.   

Abstract

The mainstay of migraine treatment is pharmacotherapy. There have been numerous medications used to prevent migraine headaches, including b-blockers, calcium-channel blockers, anticonvulsants, and nonsteroidal anti-inflammatory drugs. Sodium valproate is the only antiepileptic drug approved by the Food and Drug Administration for migraine prevention. Newer antiepileptics, including gabapentin and topiramate, are being evaluated for their role in preventive therapy. The mechanism of action of antiepileptics is not fully understood, but they all share a common role in enhancing gamma-aminobutyric acid-mediated inhibition. This article reviews the role of anticonvulsants in preventive migraine therapy.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12525273     DOI: 10.1007/s11916-003-0012-6

Source DB:  PubMed          Journal:  Curr Pain Headache Rep        ISSN: 1534-3081


  21 in total

1.  Guidelines on migraine: part 4. General principles of preventive therapy.

Authors:  S S Morey
Journal:  Am Fam Physician       Date:  2000-11-15       Impact factor: 3.292

2.  Divalproex sodium in migraine prophylaxis: a dose-controlled study.

Authors:  J Klapper
Journal:  Cephalalgia       Date:  1997-04       Impact factor: 6.292

3.  Sodium valproate in the prophylactic treatment of migraine: a double-blind study versus placebo.

Authors:  R Hering; A Kuritzky
Journal:  Cephalalgia       Date:  1992-04       Impact factor: 6.292

Review 4.  Antiepileptic drugs in migraine prevention.

Authors:  N T Mathew
Journal:  Headache       Date:  2001 Nov-Dec       Impact factor: 5.887

5.  Topiramate in migraine prevention: a double-blind, placebo-controlled study.

Authors:  J R Storey; C S Calder; D E Hart; D L Potter
Journal:  Headache       Date:  2001 Nov-Dec       Impact factor: 5.887

6.  Valproic acid is effective in migraine prophylaxis at low serum levels: a prospective open-label study.

Authors:  S Kinze; M Clauss; U Reuter; T Wolf; J P Dreier; K M Einhäupl; G Arnold
Journal:  Headache       Date:  2001-09       Impact factor: 5.887

7.  Migraine prophylaxis with divalproex.

Authors:  N T Mathew; J R Saper; S D Silberstein; L Rankin; H G Markley; S Solomon; A M Rapoport; C J Silber; R L Deaton
Journal:  Arch Neurol       Date:  1995-03

8.  Sodium valproate has a prophylactic effect in migraine without aura: a triple-blind, placebo-controlled crossover study.

Authors:  R Jensen; T Brinck; J Olesen
Journal:  Neurology       Date:  1994-04       Impact factor: 9.910

9.  A randomized trial of divalproex sodium extended-release tablets in migraine prophylaxis.

Authors:  Frederick G Freitag; S D Collins; H A Carlson; J Goldstein; J Saper; S Silberstein; N Mathew; P K Winner; R Deaton; K Sommerville
Journal:  Neurology       Date:  2002-06-11       Impact factor: 9.910

10.  Valproate: a new drug in migraine prophylaxis.

Authors:  K V Sørensen
Journal:  Acta Neurol Scand       Date:  1988-10       Impact factor: 3.209

View more
  2 in total

Review 1.  Antiepileptic drugs in non-epilepsy disorders: relations between mechanisms of action and clinical efficacy.

Authors:  Cecilie Johannessen Landmark
Journal:  CNS Drugs       Date:  2008       Impact factor: 5.749

2.  Comparison of Pregabalin and Sodium Valproate in Migraine Prophylaxis: A Randomized Double-Blinded Study.

Authors:  Omid Hesami; Mohammad Reza Shams; Ladan Ayazkhoo; Farhad Assarzadegan; Behnam Safarpour Lima; Hosein Delavar Kasmaei; Mohammad Sistanizad
Journal:  Iran J Pharm Res       Date:  2018       Impact factor: 1.696

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.